Apeiron Biologics Ag

Greenovation Biotech Gmbh

Attoquant Diagnostics Gmbh

Meridian Biopharmaceuticals Gmbh

Other

Medizinische Universitat Innsbruck

Igeneon Krebs-immuntherapie Forschungs-und Entwicklungs-ag

Apeiron Biologicals Ag

Apeiron Biologics Forschungs-und Entwicklungsgesellschaft M.b.h.

Medizinische Universitaet Innsbruck

Altropus Gmbh

Manfred Schuster

Hans Loibner

Evelyne Janzek-Hawlat

Bernhard Peball

Stefan Stranner

Gottfried Himmler

Geert Mudde

Gilbert Gorr

Gerda Redl

Oliver Mutschlechner

Ruth Ladenstein

Robert Weik

Wolfgang Jost

Cornelia Schwager

Marko Poglitsch

Ralf Kircheis

Manuela Loidl

Susanne Wiederkum

Holger Lode

Franz Groiss

Andreas Nechansky

Bettina Wagner

Günther Lametschwandtner

Günter Waxenecker

Thomas Putz

Isabella Haslinger

Sandra Seidl

Gottfried Baier

Dominik Wolf

Guenter Waxenecker

Gunther Lametschwandtner

Helmut Eckert

The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.

Method for treating a GD2 positive cancer

The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.

Method for measurement of peptidic degradation products of a proteolytic cascade in blood samples

The present invention relates to recombinant ACE2 polypeptide, where the ACE2 polypeptide is present as a dimer. The dimer is formed specifically from glycosylated monomers and is used for producing pharmaceutical products with an extended half-life.

Method for producing ACE2 polypeptide

The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.

Glyco-engineered antibodies

The present invention relates to modified angiotensin converting enzyme 2 (ACE2) polypeptides and pharmaceutical and analytical uses thereof. In particular, the present invention relates to Zndepleted-, Znfree-, mixed metal- and metal ion substituted-ACE2 as well as methods for the manufacture of these variants and uses thereof, such as therapeutic and analytic uses of these ACE2 variants.

Modified ACE2 polypeptides

The invention discloses a method for measurement of peptidic degradation products of a proteolytic cascade (for example, the renin-angiotensin system (RAS) and the bradykinin system) in biological samples, especially blood samples, wherein the sample is incubated until a steady state equilibrium is reached for at least one peptidic degradation product involved in said proteolytic cascade and wherein said at least one peptidic degradation product in steady state equilibrium of the proteolytic cascade is quantified in the sample.

The present invention relates to ACE2 for the therapeutic treatment or prevention of inflammation.

Treatment of inflammatory illnesses with ACE2

The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases.

SiRNA against Cbl-b and optionally IL-2 and IL-12 for use in the treatment of cancer

The present invention relates to an antibody preparation comprising modified antibodies of an animal or derivatives or fragments thereof, specific for an antigen, characterized in that &#x2022; the antibodies or derivatives or fragments thereof comprise an N-glycan structure free of fucose and xylose, and &#x2022; at least 90%, preferably at least 95%, more preferred at least 99%, most preferred at least 100% of the modified antibodies, derivatives or fragments thereof lack a C-terminal lysine residue.

The invention provides for innovative improvements in tumor therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity.

Treatment of tumors

The invention relates to an in vitro or ex vivo method for increasing the immunoreactivity of cells of the immune system, which were contacted with an antigen, said method comprising the reduction or inhibition of the Cbl-b function of said cells, thereby increasing the immunoreactivity of the cells towards the antigen.

Method for increasing immunoreactivity

Recombinant ACE2 polypeptide dimer

The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.

Method of treating lewis Y-expressing tumors

Methods of determining ACE2 activity in a sample by reacting the sample with ACE2-binding units immobilized on a solid carrier and specific for a part of ACE2 not involved in the catalytic activity of ACE2. The reaction provides a signal that can be correlated with the ACE2 activity. These methods allow for ACE2 activity in complex solutions, such as bodily liquids or culture supernatants, to be quantitatively determined using the endogenous activity of the enzyme to be quantified by converting a signal-providing substrate.

Method for determining ACE2 activity

Growing community of inventors

Schrick, Austria

Manfred Schuster